Lenalidomide Plus Rituximab for Indolent Non-Hodgkin's Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00695786
First received: June 10, 2008
Last updated: July 9, 2015
Last verified: July 2015